ReferenceRRK4131

TUXEDO

Phase I/II feasibility study of cetuximab with cisplatin or 5FU and Mitomycin C with concurrent radiotherapy in muscle invasive bladder cancer (TUXEDO)

Research Summary

Combining radiotherapy with drug therapy has produced impressive outcome gains in a number of cancers includingbladder cancer. We aim to combine radiotherapy (a current standard treatment) with a new drug cetuximab as well asstandard chemotherapy drugs either fluorouracil with mitomycin C or cisplatin. We will initially evaluate the safety of thecombinations. Subject to satisfactory safety data we will go on to study the preliminary efficacy of the combinationtherapy as a basis for future trials.

Research Overview
PI Name James - ND
Speciality
Sponsor University of Birmingham
Project Status Open
Proposed End Date 30/06/2017
Study Run through CRF? Yes
Target number of patients agreed to recruit 18
Recruitment so far 9